诉讼基本信息 - 律师事务所Kessler Topaz Meltzer & Check, LLP宣布，针对DexCom公司的证券集体诉讼已提起 [1] - 诉讼代表在2024年7月26日至2025年9月17日期间购买或收购DexCom证券的投资者 [1] - 首席原告的申请截止日期为2025年12月26日 [1][3] 被指控的不当行为 - 指控公司在集体诉讼期间作出虚假和/或误导性陈述，未能披露其G6和G7连续血糖监测系统进行了未经FDA授权的重大设计变更 [2] - 指控前述设计变更导致G6和G7设备可靠性降低，对依赖其获取准确血糖读数的用户构成重大健康风险 [2] - 指控公司夸大了G7设备的增强功能以及其可靠性、准确性和功能性 [2] - 指控公司淡化了有问题的G7设备所引发问题的真实严重程度和健康风险 [2] - 指控前述行为使公司面临监管审查和执法行动风险增加，以及重大的法律、声誉和财务损害风险 [2]

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 29, 2025. SO WHAT: If you purchased DexCom securities during the Class P ...

Oct 28, 2025 3:30 PM Eastern Daylight Time Rosen Law Firm Urges DexCom, Inc. (NASDAQ: DXCM) Stockholders with Large Losses to Contact the Firm for Information About Their Rights Share NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of DexCom, Inc. (NASDAQ: DXCM) securities between July 26, 2024 and September 17, 2025, both dates inclusive (the "Class Period†). DexCom is a medical d ...